19 February 2026
Johnson & Johnson's Rybrevant Faspro™ Shows 56% Response Rate in First-Line Head and Neck Cancer
The OrigAMI-4 study shows amivantamab with immunotherapy offers durable antitumor activity in recurrent/metastatic head and neck cancer, improving outcomes over current treatments.
